Results of a phase 2, placebo-controlled trial detail the potential of cendakimab, an interleukin (IL)-13 inhibitor from Bristol Myers Squibb, in the management of moderate to severe atopic dermatitis.
Conducted among a cohort of 202 patients with atopic dermatitis from nearly half a dozen countries, results of the study suggest use of cendakimab 720 mg weekly was associated with a statistically significant reduction in mean percentage change in Eczema Area and Severity Index (EASI) scores at week 16 relative to placebo therapy. Click here to read more.
